Patents by Inventor Jane Grogan

Jane Grogan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
    Publication number: 20230098521
    Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: June 15, 2022
    Publication date: March 30, 2023
    Inventors: Hilary CLARK, Dan EATON, Lino GONZALEZ, Jr., Jane GROGAN, Jason A. HACKNEY, Kristin BOWLES, Xin YU
  • Compositions and methods for the treatment of immune related diseases
    Patent number: 11390678
    Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: July 19, 2022
    Assignee: Genentech, Inc.
    Inventors: Hilary Clark, Dan Eaton, Lino Gonzalez, Jr., Jane Grogan, Jason A. Hackney, Kristin Bowles, Xin Yu
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20210340253
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: July 2, 2021
    Publication date: November 4, 2021
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20210332132
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 28, 2021
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS
    Publication number: 20200405855
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.
    Type: Application
    Filed: February 7, 2020
    Publication date: December 31, 2020
    Applicant: Genentech, Inc.
    Inventors: Jane GROGAN, Yuanyuan XIAO, Patrick CAPLAZI, Steve LIANOGLOU, Jason HACKNEY, Eugene Yu-Chuan CHIANG
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20200399366
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: March 13, 2020
    Publication date: December 24, 2020
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR
  • NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
    Publication number: 20200317773
    Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: August 9, 2019
    Publication date: October 8, 2020
    Inventors: Hilary CLARK, Dan EATON, Lino GONZALEZ, Jr., Jane GROGAN, Jason A. HACKNEY, Kristin BOWLES, Xin YU
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS
    Publication number: 20200155676
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.
    Type: Application
    Filed: June 26, 2019
    Publication date: May 21, 2020
    Applicant: Genentech, Inc.
    Inventors: Jane GROGAN, Yuanyuan XIAO, Patrick CAPLAZI, Steve LIANOGLOU, Jason HACKNEY, Eugene Yu-Chuan CHIANG
  • Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
    Patent number: 10626174
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 21, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors
    Patent number: 10611836
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 7, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Compositions and methods for the treatment of immune related diseases
    Patent number: 10377823
    Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: August 13, 2019
    Assignee: Genentech, Inc.
    Inventors: Hilary Clark, Dan Eaton, Lino Gonzalez, Jr., Jane Grogan, Jason A. Hackney, Kristin Bowles, Xin Yu
  • Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
    Patent number: 9873740
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: January 23, 2018
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS
    Publication number: 20170274073
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of a PD-1 axis binding antagonist and an IL-17 binding antagonist. Further provided are kits comprising a PD-1 axis binding antagonist, an IL-17 binding antagonist, or both, as well as instructions for use thereof.
    Type: Application
    Filed: March 2, 2017
    Publication date: September 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Jane GROGAN, Yuanyuan XIAO, Patrick CAPLAZI, Steve LIANOGLOU, Jason HACKNEY, Eugene Yu-Chuan CHIANG
  • NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
    Publication number: 20170145093
    Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: August 8, 2016
    Publication date: May 25, 2017
    Inventors: Hilary CLARK, Dan EATON, Lino GONZALEZ, JR., Jane GROGAN, Jason A. HACKNEY, Kristin BOWLES, Xin YU
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20170044256
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 16, 2017
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20170037127
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 9, 2017
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR
  • Compositions and methods for the treatment of immune related diseases
    Patent number: 9499596
    Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: November 22, 2016
    Assignee: Genentech, Inc.
    Inventors: Hilary Clark, Dan Eaton, Lino Gonzalez, Jane Grogan, Jason Hackney, Kristin Bowles, Xin Yu
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS
    Publication number: 20150216970
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: July 16, 2014
    Publication date: August 6, 2015
    Inventors: Jane GROGAN, Robert J. JOHNSTON, Bryan IRVING, Jason HACKNEY, Xin YU, Dan EATON, Kristin BOWLES, Laetitia COMPS-AGRAR
  • NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES
    Publication number: 20130251720
    Abstract: The present invention relates to compositions and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: October 9, 2012
    Publication date: September 26, 2013
    Applicant: GENENTECH, INC.
    Inventors: HILARY CLARK, DAN EATON, LINO GONZALEZ, JR., JANE GROGAN, JASON A. HACKNEY, KRISTIN HARDEN, XIN YU
  • BIOLOGICAL MARKERS PREDICTIVE OF RHEUMATOID ARTHRITIS RESPONSE TO LYMPHOTOXIN ANTAGONISTS
    Publication number: 20110263451
    Abstract: The present invention relates to a soluble lymphotoxin (solLT) and methods of using the solLT as a biomarker in the treatment of autoimmune disease. More particularly, the present invention relates to soluble lymphotoxin alpha-beta (solLT??) and methods of using this solLT?? as a biomarker in the treatment of rheumatoid arthritis (RA).
    Type: Application
    Filed: September 29, 2009
    Publication date: October 27, 2011
    Inventors: Jane Grogan, Wai Lee Wong, Judy Young